Antares Pharma (ATRS) Reports In-Line Q1 EPS

Antares Pharma (NASDAQ: ATRS) reported Q1 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $9.22 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand